Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-20-135392
Filing Date
2020-12-14
Accepted
2020-12-14 20:00:58
Documents
2
Period of Report
2020-11-15

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2038281d1_3.html 3  
1 OWNERSHIP DOCUMENT tm2038281d1_3.xml 3 1560
2 EXHIBIT 24.1 tm2038281d1_ex24-1.htm EX-24.1 11115
  Complete submission text file 0001104659-20-135392.txt   14248
Mailing Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666
Business Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666 201-329-7300
PHIBRO ANIMAL HEALTH CORP (Issuer) CIK: 0001069899 (see all company filings)

EIN.: 131840497 | State of Incorp.: DE | Fiscal Year End: 0630
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O IGI LABORATORIES, INC. 105 LINCOLN AVENUE BUENA NJ 08310
Business Address
Finio Damian (Reporting) CIK: 0001604516 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36410 | Film No.: 201387843